Codiak BioSciences   Report issue

For profit Phase 1 Phase 2
Founded: Cambridge MA United States (2015)

Organization Overview

First Clinical Trial
2020
NCT04592484
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Codiak BioSciences

Active Ingredients

Drugs in Phase 2 Trials (1)

cdk-002 (1 trial)

Drugs in Phase 1 Trials (2)

cdk-003 (1 trial)

exoASO-STAT6 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3